












Gabriel Ocana Santero
CEO at Exin Therapeutics
Neuroscientist with a background in biochemistry and research on gene therapy, pancreatic cancer, and muscle physiology at institutions in Boston, Vienna, and Stockholm. Earned MSc in Neuroscience and PhD in Pharmacology at Oxford Uni, focusing on neurodevelopment and the effects of SSRI anti-depressants on early patterns of neural activity. Used neuroAI models at the Gatsby Unit (UCL) to study serotonin’s role in cognition. Currently developing gene therapies for neurological conditions.
Follow Gabriel
Previously at
Gatsby Computational Neuroscience Unit

University of Oxford
Karolinska Institutet (Stockholm)
Institute for Cancer research (Medical University of Vienna)
Alumnus of

University of Oxford
Universidad Autónoma de Madrid
I.E.S. Marques de Suanzes